Tadalafil became famous for the wrong reason. Longevity physicians now prescribe it daily at low doses for endothelial health, vascular protection, and cerebral perfusion — not for erectile dysfunction. Here is the full protocol, the evidence, and what to track.
Tadalafil has a branding problem. It got famous as the drug in the Cialis ads, and that association has obscured something important: it is one of the most mechanistically compelling cardiovascular longevity compounds available, and it has 20 years of clinical safety data behind it.
Every serious longevity physician who thinks carefully about vascular health has at some point considered daily low-dose tadalafil. Many prescribe it. Not for erectile dysfunction — as a vascular maintenance protocol.
Tadalafil is a PDE5 inhibitor. PDE5 (phosphodiesterase type 5) is an enzyme that breaks down cyclic GMP (cGMP) in smooth muscle cells. cGMP is the downstream messenger of nitric oxide — the molecule that tells your blood vessels to relax and dilate.
When PDE5 breaks down cGMP, blood vessels constrict. When tadalafil blocks PDE5, cGMP accumulates, nitric oxide signals are prolonged, and smooth muscle stays relaxed. The result is vasodilation — sustained, systemic, affecting every blood vessel in your body.
This is not a localized effect. Tadalafil at therapeutic concentrations reaches the coronary arteries, the pulmonary vasculature, the cerebral circulation, the kidneys, and skeletal muscle. Every downstream organ that depends on good blood flow benefits from sustained PDE5 inhibition.